A person with gout may spend several months without pain and assume that the disease has settled down. The foot looks normal again, shoes fit comfortably, walking is easier. Then, sometimes without an obvious reason, another attack occurs. The big toe is a common target, but the knee, ankle, wrist and fingers are also vulnerable. What is happening during the quiet period is less visible. Urate crystals can remain in the tissues even when the joint no longer looks inflamed. If their accumulation continues, the problem gradually extends beyond painful episodes and begins to affect the physical structure of the joint.
Gouty arthritis develops when monosodium urate crystals accumulate in and around joints. Their formation is associated with an elevated concentration of urate in the blood, usually because the kidneys do not eliminate enough of it, although increased production can also play a part. Some people have high uric acid levels for years without developing gout. Others experience their first attack without having known that their urate concentration was elevated. The distinction matters: a blood test showing hyperuricemia cannot, by itself, establish the diagnosis.
The inflammatory reaction is driven by the body’s response to the crystals. Once deposited in the joint, they can activate immune cells and trigger the release of inflammatory substances, including interleukin-1 beta. The resulting attack may be severe. The affected area becomes hot, swollen and intensely painful; even the pressure of a bedsheet against the foot can be intolerable. An episode often begins abruptly, sometimes during the night. It may improve over several days, although the duration varies and untreated attacks can last longer.
Repeated inflammation changes the conditions inside the joint. The synovial membrane may remain irritated, cartilage can become damaged, and erosions may develop in the underlying bone. In advanced gout, collections of crystals form visible or palpable nodules called tophi. They can appear around the fingers, elbows, toes and Achilles tendon. A tophus is not simply a lump beneath the skin. Depending on its position and size, it can interfere with tendon movement, press on nearby nerves, damage surrounding tissue or make ordinary joint movement difficult. When the skin over a deposit becomes thin or breaks down, the area can ulcerate and become vulnerable to infection.
The knee presents a particular functional problem because even a relatively short period of painful inflammation can change the way a person walks. Fluid inside the joint restricts movement, and the patient may keep the knee slightly flexed to avoid discomfort. The quadriceps then has to work under different conditions. Muscle inhibition, reduced loading and avoidance of movement can leave the leg weaker after the visible swelling has disappeared. Full extension may remain difficult. A person can have less pain but still struggle with stairs, standing up from a low chair or walking at the usual speed. These limitations deserve examination in their own right. They are not always explained by the level of uric acid in the blood.
There is another reason not to assume that every red, swollen joint is gout. Bacterial infection inside a joint can look almost identical at the beginning, and septic arthritis is an urgent condition. Cartilage can be damaged quickly when infection is left untreated. Fever may be absent, so its absence offers little reassurance. Even if urate crystals are found in the joint fluid, infection has not automatically been excluded. Both conditions can occur at the same time. When septic arthritis is suspected, aspiration of the joint and microbiological testing are essential parts of the investigation.
Examination of the joint fluid under polarized light can reveal the characteristic needle-shaped monosodium urate crystals, which show strong negative birefringence. This finding provides direct evidence of crystal deposition. A serum urate measurement is useful for assessing the patient’s metabolic state and planning long-term treatment, but the timing of the test matters. During an acute attack, the measured level can temporarily fall and may even be within the laboratory reference range. If the result does not fit the clinical picture, it should be repeated after the inflammation has settled. Kidney function also needs attention, since impaired renal clearance is a frequent contributor to persistent hyperuricemia and affects the choice and dose of medication.
Imaging can help establish how far the disease has progressed. An X-ray may reveal bone erosions in longstanding gout, but an early radiograph can show very little. Ultrasound is able to identify deposits in and around joints, while dual-energy CT can distinguish urate material from other tissues. These methods are particularly useful when the diagnosis remains uncertain or when the extent of crystal deposition needs to be assessed. They do not replace joint aspiration when infection is a concern.
During an acute episode, treatment aims to suppress inflammation and make movement tolerable again. Nonsteroidal anti-inflammatory drugs, colchicine and corticosteroids are among the medicines used. The choice cannot be made on the basis of pain intensity alone. A patient with chronic kidney disease may not be a suitable candidate for certain anti-inflammatory drugs; someone with a history of gastrointestinal bleeding or cardiovascular disease also requires a different risk assessment. Colchicine has important interactions with some medications and can cause toxicity when used incorrectly. Corticosteroids may be given orally or injected into the joint, but an injection must wait until infection has been adequately excluded.
Once the attack has passed, the decision about long-term treatment becomes central. If crystals continue to accumulate, another episode is only part of the possible outcome. Progressive deposits can produce tophi and permanent joint damage. Urate-lowering medication is used to reduce the concentration of urate sufficiently for existing crystals to dissolve over time and for new deposits to become less likely. Allopurinol is commonly prescribed as the initial treatment. Febuxostat is another option when clinically appropriate. The dose is adjusted according to blood urate measurements, kidney function and treatment response. For most patients, the target is below 6 mg/dL, or 360 µmol/L. People with severe tophaceous disease may need a lower target.
The first months of urate-lowering treatment can be confusing for patients. Attacks may occur after treatment has started, even when the medication is doing what it is supposed to do. Changes in urate concentration can disturb existing deposits and temporarily provoke inflammation. For this reason, clinicians often prescribe preventive low-dose colchicine or another suitable anti-inflammatory medicine when starting or increasing urate-lowering therapy. Patients should not interpret an early flare as proof that the treatment has failed, and they should not discontinue prescribed medication without discussing it with their clinician. Long-term control depends on maintaining the target urate concentration, not on waiting for pain to return before taking action.
Food choices are relevant, although they rarely explain the entire disease. Organ meats, some seafood, large amounts of red meat, beer and spirits can contribute to a higher risk of attacks. Drinks containing substantial amounts of fructose are another concern. A balanced diet, gradual weight reduction when needed and adequate fluid intake can support treatment, particularly in people with metabolic syndrome or a history of kidney stones. Severe fasting and rapid weight-loss programmes are poor approaches for someone prone to gout because abrupt metabolic changes can raise urate levels. Dietary changes are useful, but they cannot reliably remove established crystal deposits in a person with persistent gout.
Orthopedic treatment is sometimes needed when the consequences have become mechanical. A large tophus may restrict finger movement, interfere with a tendon or repeatedly damage the skin. Deposits around the Achilles tendon can affect walking and, in advanced cases, compromise the tendon itself. Surgery may be considered when there is substantial functional impairment, nerve compression, recurrent ulceration or severe joint destruction. Removing a deposit does not correct the metabolic cause of gout. Without effective urate control, further crystal accumulation remains possible.
Rehabilitation has to take account of the stage of the disease. Exercising aggressively during an acute inflammatory attack can aggravate pain and irritate the affected tissues. After the acute reaction has subsided, prolonged protection can create a different set of problems. The knee may need gradual restoration of extension and flexion, followed by quadriceps strengthening and gait training. After an attack in the foot or ankle, the focus may be on comfortable weight-bearing, balance and walking mechanics. If the hands are affected, even basic tasks such as fastening buttons, opening containers or holding kitchen utensils may require attention. The programme should reflect the actual limitation, rather than follow the same routine for every person with gout.
For an orthopedic specialist, the important question is often what the patient can still do. Can the person walk without shifting weight away from the painful side? Does the knee straighten fully? Can the fingers close around an object? Is a tendon functioning normally, or has a deposit begun to interfere with its movement? These findings help determine whether the patient needs rehabilitation, further imaging, surgical assessment or closer coordination with a rheumatologist. Gout is primarily a metabolic and inflammatory disease, but its consequences are often measured in lost movement and reduced independence.
The disappearance of an attack is not a reliable measure of disease control. A joint may become comfortable while urate deposits remain, and structural changes can continue unnoticed until movement becomes restricted. Consistent urate-lowering treatment, appropriate management of acute inflammation and attention to the physical condition of the affected limb all have a place in care. The aim is not merely to make the next attack less painful. It is to prevent the disease from gradually taking away the movements that a person relies on every day.